CXCR4

(redirected from CD184)

CXCR4

A gene on chromosome 2q21 that encodes a seven-transmembrane G protein-coupled receptor belonging to the CXC chemokine receptor family, which binds specifically to stromal cell-derived factor-1, transducing a signal by increasing intracellular calcium ions and enhancing MAPK1/MAPK3 activation. It acts as a receptor for extracellular ubiquitin, is involved in haematopoiesis and in cardiac ventricular septum formation, plays a role in gastrointestinal tract vascularisation by regulating vascular branching and/or remodelling in endothelial cells, may be involved in cerebellar development and, in the CNS, may mediate hippocampal-neuron survival.

Molecular pathology
CXCR4 acts with the CD4 to support HIV entry into cells; it is highly expressed in breast cancer cells. CXCR4 mutations cause WHIM (warts, hypogammaglobulinaemia, infections, and myelokathexis) syndrome.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
[ELR.sup.-] chemokines are commonly angiostatic, but CXCL12 (previously known as stromal cell-derived factor 1, abbreviated as SDF1) [10] and its receptor, CXCR4 (previously known as LESTR, fusion, or CD184), are reported to promote angiogenesis and play a major role in metastasis.
The immunophenotypic profile was analyzed using the antibodies CD14, CD34, CD44, CD45, CD73, CD90, CD146, CD184, Stro-1 and HLA-DR (Becton Dickinson, USA) conjugated with FITC or PE fluorochrome.
Some antigens presented low expression: CD34 (3.15 [+ or -] 1.75%), CD184 (0.6 [+ or -] 0.6%), and STRO-1 (2.8 [+ or -] 2.5%) and others presented negative expression: CD14, CD45 and HLA-DR.
Chemokine receptors CXCR4 (CD184) and CCR5 (CD195) are predominant coreceptors for HIV-1 entry into human's cells.
Schwartz et al (20) demonstrated high levels of the neural stem cell markers like CD133, CD44, CD81, CD184, CD90, and CD29 positive but CD133 cell population was decreased in high-passage, lineage-restricted cultures.
Figure 1 demonstrates an example of k LC-restricted CBLs with the following surface phenotypic marker expression profile: [CD34.sup.+] (partial), [CD44.sup.+], HLA-[DR.sup.+], CD31 (partial), CD184, CD45RO (partial), [CD50.sup.+], [CD10.sup.-], [CD11b.sup.-], [CD14.sup.-], [CD19.sup.-], [CD20.sup.-], [CD49d.sup.-], [CD54.sup.-], [CD56.sup.-], [CD62L.sup.-], [CD117.sup.-], [CD126.sup.-], [CD130.sup.-], and [CD138.sup.-].
The phenotypic characteristics of ADRCs from the SVF were analyzed by flow cytometry in a subset of 15 sequentially enrolled patients (CD34: 70.4% (range 66.5-73.3), CD45: 21.9% (range 17.3-26.0), CD184: 13.8% (range 6.9-17.1), vascular endothelial growth factor receptors: 10.8% (range 6.7-17.3), CD31: 10.3% (range 8.7-14.5), CD71: 2.8% (range 1.3-5.7), and CD105: 1.7% (range 0.6-2.6)).
[10.sup.6] cells were incubated with the following conjugated antibodies against human cell surface molecules: CD29, CD34 (hematopoietic stem/progenitor cells/endothelium), CD44, CD45, CD73, CD90 (common leukocyte antigens), HLA-DR (human leukocyte antigen, class II), CD14 (monocyte/macrophage), CD184 and STRO-1 (Stromal Cell Surface Marker) (PharMingen-BD Biosciences, USA), conjugated with FITC (Santacruz, USA) or PE (PharMingen-BD Biosciences).
Comparably to their minimal expression profiles observed in hepatocytes, the cell surface receptors CD45, CD95, CD184, CD200R, CD210, CD229, and CD271 showed a very weak, if any, expression in undifferentiated as well as hepatic-differentiated ADHLSCs.
In this study, we used flow cytometry to analyse the effects of short-term hypoxic stress on the expression of CD29 (integrin [beta]1), CD44 (HCAM), CD49d (integrin [alpha]4), CD49e (integrin [alpha]5), CD51 (integrin aV), CD61 (integrin [beta]3), and CD184 (CXCR4).
The surface expression of CXCR4 and CXCR7 on CB-derived MSC was examined using PE-conjugated antihuman CD184 (CXCR4, clone 12G5, BD Biosciences Mississauga, ON, Canada) and PE-conjugated antihuman CXCR7 (clone 11G8, R&D Systems, Minneapolis, MN, USA).